Cytokinetics' reldesemtiv misses COPD, frailty endpoints
Cytokinetics Inc. (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo:4503) said reldesemtiv (CK-2127107) missed the primary and secondary endpoints in a Phase II trial to treat chronic obstructive pulmonary disease. The partners also said an interim analysis by an IDMC of a Phase Ib trial evaluating the effect of reldesemtiv on skeletal muscle fatigue in elderly subjects with limited mobility met the predefined criteria for lack of efficacy.
Cytokinetics spokesperson Diane Weiser told BioCentury the partners are conducting additional analyses of the data to determine next steps for the fast skeletal muscle troponin activator in the indications. The partners’ neuromuscular program for reldesemtiv will continue to evaluate the compound to treat spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS)...